Medical Center Medconsult Pleven OOD
- Address
- Floor 4, Ulitsa Sveti Sveti Kiril I Metodiy 18, 5800 Pleven, Bulgaria
Cardiovascular Disease Research
The team at Medical Center Medconsult Pleven OOD focuses on improving outcomes for patients with cardiovascular disease and related conditions, exploring both preventive strategies and novel therapeutic options.
- Primary prevention of atherosclerotic events
- Management of heart failure with preserved ejection fraction
- Blood‑clot prevention in atrial fibrillation
- Lipid‑lowering strategies for high‑risk patients
- Evaluation of new anticoagulant agents
With over 118 trials conducted by eight investigators, the site contributes significantly to cardiovascular innovation across Europe.
Respiratory & Allergy Research
Investigations target chronic airway diseases and allergic disorders, aiming to reduce exacerbations and improve quality of life for individuals with asthma, chronic obstructive pulmonary disease, and seasonal allergies.
- Severe asthma exacerbation reduction
- Long‑term safety of COPD inhaler regimens
- Allergen immunotherapy for grass pollen allergy
- Management of chronic rhinosinusitis with nasal polyps
- Antiviral therapy for respiratory syncytial virus in adults
The facility’s multidisciplinary approach supports both pediatric and adult populations in the Pleven region.
Immune‑Mediated & Skin Research
The center conducts extensive studies on autoimmune and inflammatory skin conditions, evaluating biologic and small‑molecule therapies for diseases such as psoriatic arthritis, atopic dermatitis, and lupus erythematosus.
- Biologic therapy assessment in psoriatic arthritis
- Topical and systemic options for atopic dermatitis
- Urticaria activity score improvement trials
- Cutaneous lupus disease activity monitoring
- Hidradenitis suppurativa treatment investigations
These efforts address both adult and adolescent patients, reflecting the site’s commitment to dermatologic health.
Neurology & Mental Health Research
Clinical programs explore therapies for neuro‑degenerative and psychiatric disorders, including multiple sclerosis, Alzheimer’s disease, schizophrenia, and generalized anxiety disorder.
- Relapse reduction in relapsing‑remitting multiple sclerosis
- Agitation management in Alzheimer’s dementia
- Adjunctive treatments for treatment‑resistant schizophrenia
- Novel agents for generalized anxiety disorder
- Cognitive performance enhancement in schizophrenia
The research supports both acute symptom control and long‑term disease modification.
Metabolic & Endocrine Research
Studies address metabolic dysfunctions, focusing on conditions such as hypertriglyceridemia, obesity‑related cardiovascular risk, and post‑menopausal osteoporosis, as well as rare disorders like exocrine pancreatic insufficiency.
- Lipid‑lowering agents for severe hypertriglyceridemia
- Bone density improvement in osteoporosis
- Management of pancreatic enzyme deficiency
- Weight‑related cardiovascular risk reduction strategies
- Evaluation of novel metabolic biomarkers
These trials aim to enhance metabolic health and reduce associated complications.
Infectious Disease & Virology Research
The site participates in antiviral and vaccine‑adjunct studies targeting influenza, SARS‑CoV‑2, and respiratory syncytial virus, seeking to improve treatment outcomes for high‑risk populations.
- Antiviral efficacy in COVID‑19
- Treatment of influenza in high‑risk adults
- RSV therapeutic development for older adults
- Safety of novel antivirals in immunocompromised patients
- Vaccine adjunct studies to boost immune response
Ongoing collaborations enhance the center’s capacity to respond to emerging infectious threats.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 14 therapeutic areas and 15 of 210 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 207 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 32 by active trials.
- 1Novartis Pharma AG3active
lock +31 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG12trials
lock +24 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Medconsult Pleven OOD
lock Showing 1 of 116 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 210 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 5 | Unknown | 2023-03-22 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.